{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:44:54Z","timestamp":1780418694355,"version":"3.54.1"},"reference-count":34,"publisher":"BMJ","funder":[{"name":"European Union\u2019s Horizon 2020","award":["633168 \u2014 BIOCYCLE (PHC-13-2014)"],"award-info":[{"award-number":["633168 \u2014 BIOCYCLE (PHC-13-2014)"]}]},{"name":"Walloon Region and the Fond europ\u00e9en de d\u00e9veloppement r\u00e9gional","award":["246099-510388"],"award-info":[{"award-number":["246099-510388"]}]},{"name":"Liege University Hospital","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2024,7,28]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>In patients with Crohn\u2019s disease (CD) on combination therapy (infliximab and immunosuppressant) and stopping infliximab (cohort from the study of infliximab diSconTinuation in CrOhn\u2019s disease patients in stable Remission on combined therapy with Immunosuppressors (STORI)), the risk of short-term (\u22646 months) and mid\/long-term relapse (&gt;6 months) was associated with distinct blood protein profiles. Our aim was to test the external validity of this finding in the SPARE cohort (A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy).<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>In SPARE, patients with CD in sustained steroid-free clinical remission and on combination therapy were randomly allocated to three arms: continuing combination therapy, stopping infliximab or stopping immunosuppressant. In the baseline serum of the STORI and SPARE (arm stopping infliximab) cohorts, we studied 202 immune-related proteins. The proteins associated with time to relapse (univariable Cox model) were compared between STORI and SPARE. The discriminative ability of biomarkers (individually and combined in pairs) was evaluated by the c-statistic (concordance analysis) which was compared with C-reactive protein (CRP), faecal calprotectin and a previously validated model (CEASE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In STORI and SPARE, distinct blood protein profiles were associated with the risk of short-term (eg, high level: CRP, haptoglobin, interleukin-6, C-type lectin domain family 4 member C) and mid\/long-term relapse (eg, low level: Fms-related tyrosine kinase 3 ligand, kallistatin, fibroblast growth factor 2). At external validation, the top 10 biomarker pairs showed a higher c-statistic than the CEASE model, CRP and faecal calprotectin in predicting short-term (0.76\u20130.80 vs 0.74 vs 0.71 vs 0.69, respectively) and mid\/long-term relapse (0.66\u20130.68 vs 0.61 vs 0.52 vs 0.59, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with CD stopping infliximab, we confirm that the risk of short-term and mid\/long-term relapse is associated with distinct blood protein profiles showing the potential to guide infliximab withdrawal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00571337\">NCT00571337<\/jats:ext-link>and<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02177071\">NCT02177071<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/gutjnl-2024-332648","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T19:45:31Z","timestamp":1723491931000},"page":"gutjnl-2024-332648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["External validation of serum biomarkers predicting short-term and mid\/long-term relapse in patients with Crohn\u2019s disease stopping infliximab"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct00571337","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02177071","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00571337","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02177071","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8324-0434","authenticated-orcid":false,"given":"Nicolas","family":"Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2n Anh","family":"Huynh-Thu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Baiwir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Mazzucchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Fl\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Trzpiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthier","family":"Eppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"De Pauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-6676","authenticated-orcid":false,"given":"David","family":"Laharie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Satsangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-7365","authenticated-orcid":false,"given":"Peter","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucine","family":"Vuitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vieujean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Alice","family":"Meuwis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"2024081210201254000_gutjnl-2024-332648v1.1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00302","article-title":"Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease","volume":"6","author":"Louis","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2024081210201254000_gutjnl-2024-332648v1.2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/ecco-jcc\/jjad001","article-title":"ECCO Topical Review on Biological Treatment Cycles in Crohn\u2019s disease","volume":"17","author":"Noor","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2024081210201254000_gutjnl-2024-332648v1.3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.055"},{"key":"2024081210201254000_gutjnl-2024-332648v1.4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/apt.13547","article-title":"Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis","volume":"43","author":"Kennedy","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2024081210201254000_gutjnl-2024-332648v1.5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S2468-1253(19)30186-4","article-title":"De-escalation of immunomodulator and biological therapy in inflammatory bowel disease","volume":"5","author":"Chapman","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.09.034"},{"key":"2024081210201254000_gutjnl-2024-332648v1.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327321"},{"key":"2024081210201254000_gutjnl-2024-332648v1.8","doi-asserted-by":"crossref","unstructured":"Pierre N , Baiwir D , Huynh-Thu VA , et al . Discovery of biomarker candidates associated with the risk of short-term and mid\/long-term relapse after infliximab withdrawal in Crohn\u2019s patients: a proteomics-based study. Gut 2020. doi:10.1136\/gutjnl-2020-322100. [Epub ahead of print 26 Oct 2020].","DOI":"10.1136\/gutjnl-2020-322100"},{"key":"2024081210201254000_gutjnl-2024-332648v1.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100089","article-title":"Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises","volume":"3","author":"Alsoud","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"2024081210201254000_gutjnl-2024-332648v1.10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.gastro.2021.05.005","article-title":"Selecting the Ideal Candidate for Anti-TNF Discontinuation in Crohn\u2019s Disease, Dream or Reality?","volume":"161","author":"Verstockt","year":"2021","journal-title":"Gastroenterology"},{"key":"2024081210201254000_gutjnl-2024-332648v1.11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/MEG.0000000000002403","article-title":"Validation and update of a prediction model for risk of relapse after cessation of anti-TNF treatment in Crohn\u2019s disease","volume":"34","author":"Ten Bokkel Huinink","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2024081210201254000_gutjnl-2024-332648v1.14","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0698"},{"key":"2024081210201254000_gutjnl-2024-332648v1.15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"2024081210201254000_gutjnl-2024-332648v1.16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"JOSS"},{"key":"2024081210201254000_gutjnl-2024-332648v1.17","doi-asserted-by":"crossref","unstructured":"Wickham H . Ggplot2: elegant graphics for data analysis. 2nd edn. Springer Publishing Company, Incorporated, 2009.","DOI":"10.1007\/978-0-387-98141-3"},{"key":"2024081210201254000_gutjnl-2024-332648v1.18","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ecco-jcc\/jjad086","article-title":"Defining Biological Remission in Crohn\u2019s Disease: interest, Challenges and Future Directions","volume":"17","author":"Pierre","year":"2023","journal-title":"J Crohn's Colitis"},{"key":"2024081210201254000_gutjnl-2024-332648v1.19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy","volume":"13","author":"Cueto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024081210201254000_gutjnl-2024-332648v1.20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00227","article-title":"C-Type Lectin-Like Receptors As Emerging Orchestrators of Sterile Inflammation Represent Potential Therapeutic Targets","volume":"9","author":"Chiffoleau","year":"2018","journal-title":"Front Immunol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300820"},{"key":"2024081210201254000_gutjnl-2024-332648v1.22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.006"},{"key":"2024081210201254000_gutjnl-2024-332648v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.024"},{"key":"2024081210201254000_gutjnl-2024-332648v1.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01315","article-title":"IL-10 and IL-22 in Mucosal Immunity: Driving Protection and Pathology","volume":"11","author":"Wei","year":"2020","journal-title":"Front Immunol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12242"},{"key":"2024081210201254000_gutjnl-2024-332648v1.26","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1016\/j.cgh.2023.01.033","article-title":"Preclinical Serological Signatures are Associated With Complicated Crohn\u2019s Disease Phenotype at Diagnosis","volume":"21","author":"Choung","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024081210201254000_gutjnl-2024-332648v1.27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328421"},{"key":"2024081210201254000_gutjnl-2024-332648v1.28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.007"},{"key":"2024081210201254000_gutjnl-2024-332648v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu207"},{"key":"2024081210201254000_gutjnl-2024-332648v1.30","doi-asserted-by":"crossref","unstructured":"Pierre N , Baiwir D , Huynh-Thu VA , et al . Data from: Discovery of biomarker candidates associated with the risk of short-term and mid\/long-term relapse after infliximab withdrawal in Crohn\u2019s patients: a proteomics-based study. Panorama 2020. Available: https:\/\/panoramaweb.org\/atQBcH.url","DOI":"10.1136\/gutjnl-2020-322100"},{"key":"2024081210201254000_gutjnl-2024-332648v1.31","doi-asserted-by":"crossref","unstructured":"Pierre N , Huynh-Thu VA , Baiwir D , et al . Data from: External validation of serum biomarkers predicting short-term and mid\/long-term relapse in patients with Crohn\u2019s disease stopping infliximab. Panorma 2024. Available: https:\/\/panoramaweb.org\/7PNxFY.url","DOI":"10.1136\/gutjnl-2024-332648"},{"key":"2024081210201254000_gutjnl-2024-332648v1.32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/ecco-jcc\/jjy158","article-title":"Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review","volume":"13","author":"Gisbert","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2024081210201254000_gutjnl-2024-332648v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2015"},{"key":"2024081210201254000_gutjnl-2024-332648v1.34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","article-title":"Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling","volume":"20","author":"Petrera","year":"2021","journal-title":"J Proteome Res"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-332648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T16:54:12Z","timestamp":1732640052000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-332648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":34,"alternative-id":["10.1136\/gutjnl-2024-332648"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-332648","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]}}}